Thu Sep 19 06:15:57 UTC 2024: ## Annexon (ANNX) Receives “Buy” Rating from Analysts, Shares Trade Above $6

**New York, NY** – Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company focused on inflammatory-related diseases, has been assigned a consensus rating of “Buy” by six research firms covering the stock. The average 12-month price target among analysts is $15.80.

Several analysts have recently reiterated their bullish outlook on Annexon, including Cantor Fitzgerald, HC Wainwright, and Needham & Company LLC. Notably, HC Wainwright set a target price of $30.00, while Needham & Company LLC projected a $16.00 price target.

Large investors have also shown confidence in Annexon, with several institutions increasing their positions in the company during recent quarters. Ameritas Investment Partners Inc. notably raised its stake in Annexon by 78.2% in the first quarter, while Sandia Investment Management LP and Victory Capital Management Inc. both acquired new positions in the second quarter.

Shares of ANNX opened at $6.93 on Thursday, trading above both its 50-day and 200-day moving averages. The company’s market capitalization currently stands at $640.42 million. Annexon’s lead candidate, ANX005, is currently in Phase 3 clinical trials for the treatment of Guillain-Barré syndrome, and is being investigated for potential treatments of Huntington’s disease and Amyotrophic Lateral Sclerosis (ALS).

While Annexon reported a loss of $0.23 per share in the most recent quarter, analysts are predicting a loss of $0.97 per share for the current year.

**Disclaimer:** This news article is based on information from MarketBeat.com and should not be considered financial advice. Always conduct thorough research and consult with a qualified professional before making any investment decisions.

Read More